Webinar Date/Time: Tuesday, October 24th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Industry-wide, clinical trial protocols continue to increase in complexity over time. This webinar adds to the growing evidence of which elements of trial design and strategy correlate with lower study recruitment, increased timelines, and cost to help mitigate their potential impact during protocol development.
Register Free: https://www.pharmexec.com/pe_w/protocol-design-complexity
Event Overview:
Industry-wide, clinical trial protocols continue to increase in complexity over time. This webinar adds to the growing evidence of which elements of trial design and strategy correlate with lower study recruitment, increased timelines, and cost.
Connecting protocol complexity with trial outcomes provides insight to allow for better designed protocols that sites and patients want to participate in. Consequently, there is less potential for operational errors resulting in deviations and amendments and efficacy and safety is determined more efficiently, moving potential treatments more swiftly to patients who need them.
Three key take-aways
In this webinar, data science experts will present:
Speakers:
Denise Messer
Design Analytics Director
IQVIA
Denise Messer is a design analytics director at IQVIA. She has over 25 years of experience in research and clinical trials, including expertise in clinical trial planning and design. She has spoken at conferences and has been published in industry journals covering topics such as assessing and scoring trial patient burden, highlighting the voice of the patient in trial design, and assessing protocol complexity.
At IQVIA, she helped develop the IQVIA Data-informed Protocol Assessment (DIPA), using data to highlight areas for protocol optimization before operationalization, including creation of a patient burden algorithm and protocol scoring benchmarks.
Steven Zhang
Global Analytics Manager
IQVIA
Steven Zhang is a global analytics manager at IQVIA. He has more than seven years of experience in the Healthcare Tech industry, with a strong expertise in data science and machine learning. He started his career working on leveraging AI to personalize treatment selection in depression.
As a data scientist for this IQVIA project, he was responsible for the data processing and exploration regarding both the enrollment strategy and operational metrics. Combined with insights on clinical trial protocols, Steven analyzed what factors from protocols contribute to complexity and their impact on study benchmarks such as cycle times and other trial performance outcomes.
Steven holds a Master of Science degree in Neuroscience from McGill University.
Register Free: https://www.pharmexec.com/pe_w/protocol-design-complexity
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.